Stock listing

OTC:OTSKF Otsuka Holdings Co., Ltd. Stock

US listing (OTC) of Otsuka Holdings Co., Ltd. · home listing Tokyo:4578

Follow Otsuka Holdings Co., Ltd. into a list and get an email when it puts out news.

Share price · OTC:OTSKF

$73.16 USD 0.00 (0.0%)

Close on Oct 19, 2026

Day range
$73.16 – $73.16 USDOct 19, 2026
Market cap
$38.38B USDAt the close on Oct 19, 2026 · price × 524.6M shares outstanding
Otsuka Holdings Co., Ltd. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
OTC:OTSKY$38.72 USD+0.08 (+0.2%)8,013$38.76$38.80$38.72$38.64Close on Oct 19, 2026
OTC:OTSKF$73.16 USD0.00 (0.0%)—$73.16$73.16$73.16$73.16Close on Oct 19, 2026
Frankfurt:OS1€69.50 EUR+1.00 (+1.5%)—€68.50€69.50€68.50€68.50Close on Oct 20, 2026
Munich:OS1€70.50 EUR+1.50 (+2.2%)12€69.00€70.50€69.00€69.00Close on Oct 20, 2026
Ticker
OTC:OTSKF
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
OTC
Currency
USD

What changed lately

Latest news

Otsuka Completes Rolling Submission of Supplemental Biologics License Application (sBLA) for Traditional Approval of VOYXACT in U.S.

Oct 7, 2026

NDA Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA RTOR Program

Oct 1, 2026

Notice regarding the status of share repurchases

Oct 1, 2026

Otsuka Announces Transformative Phase 3 FUSION Results for Ulefnersen, Bringing the FUS-ALS Community Closer to a Potential Targeted Treatment

Sep 22, 2026

Otsuka Presents New Phase 3b Results for SIMTRIYO® (centanafadine) Highlighting Consistent Improvements Across ADHD Symptoms, Anxiety, and Associated Features in Adults with ADHD and Comorbid Anxiety Disorders at Psych Congress 2026

Sep 18, 2026

Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median PFS Benefit in Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation NSCLC

Sep 13, 2026

Zipalertinib Plus Chemotherapy Meets Primary PFS Endpoint in Planned Interim Analysis of Phase 3 REZILIENT3 Trial

Aug 12, 2026

Otsuka Unveils Unprecedented Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Stabilizes Kidney Function Decline to Baseline Physiologic Rate, Fundamentally Altering Disease Progression in IgA Nephropathy (IgAN)

Aug 3, 2026

Consolidated Financial Results for the Six-Month Period Ended June 30, 2026 [IFRS]

Jul 31, 2026

Notice Regarding Revisions of Consolidated Results Forecast for the first half of FY2026

Jul 27, 2026

All Otsuka Holdings Co., Ltd. news

Otsuka Holdings Co., Ltd. on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
14 in the last 12 months · 14 in all · newest Oct 7, 2026 · oldest 2026

Where Otsuka Holdings Co., Ltd. is listed

ListingExchangeCountryCurrency
Tokyo:4578 大塚ホールディングス · Home listingTokyoJapanJPY
OTC:OTSKYOTCUnited StatesUSD
OTC:OTSKF · This pageOTCUnited StatesUSD
gettex:OS1gettexGermanyEUR
Lang & Schwarz:A1C9KCLang & SchwarzGermanyEUR
LS Exchange:A1C9KCLS ExchangeGermanyEUR
Stuttgart:OS1StuttgartGermanyEUR
Tradegate:OS1TradegateGermanyEUR
BIVA:4578NBIVAMexicoMXN
Frankfurt:OS1FrankfurtGermanyEUR
Munich:OS1MunichGermanyEUR
BMV:4578NBMVMexicoMXN

Log in to ask 6ix AI your own questions about Otsuka Holdings Co., Ltd.